Loading…
Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer
Purpose Despite curative-intent treatment, recurrence is common for patients with colorectal cancer (CRC). Currently, prediction of disease recurrence and prognostication following surgery is based upon vague clinical factors and more precise and dynamic biomarkers for risk stratification and treat...
Saved in:
| Published in: | Journal of gastrointestinal cancer 2023-12, Vol.54 (4), p.1071-1081 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c347t-50851a4108a6d15075a2b2ade39b687e48e0dc29dae0a5ce44e0d40c5a48faba3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c347t-50851a4108a6d15075a2b2ade39b687e48e0dc29dae0a5ce44e0d40c5a48faba3 |
| container_end_page | 1081 |
| container_issue | 4 |
| container_start_page | 1071 |
| container_title | Journal of gastrointestinal cancer |
| container_volume | 54 |
| creator | Adams, Alexandra M. Vreeland, Timothy J. Newhook, Timothy E. |
| description | Purpose
Despite curative-intent treatment, recurrence is common for patients with colorectal cancer (CRC). Currently, prediction of disease recurrence and prognostication following surgery is based upon vague clinical factors and more precise and dynamic biomarkers for risk stratification and treatment decisions are urgently needed. Circulating tumor DNA (ctDNA) is a promising biomarker for patients undergoing treatment for resectable CRC.
Methods
In this review, we provide an overview of the data supporting current uses of ctDNA for CRC, including localized CRC and resectable colorectal liver metastases (CLM), as well as descriptions of important ongoing clinical trials using ctDNA in the care of patients with CRC.
Results
The detection of ctDNA following curative-intent therapy is associated with disease recurrence, and multiple trials are investigating its role in determining need and duration for adjuvant therapy for localized CRC. In addition, ctDNA reliably predicts prognosis for patients with CLM, with trials underway studying ctDNA-guided treatment sequencing and intensity.
Conclusion
The detection of ctDNA is a sensitive and dynamic biomarker for disease recurrence in CRC. Many investigations are underway into ctDNA’s potential role in surveillance and treatment algorithms, and it has the potential to become a critical biomarker to determine individualized strategies for treatment sequencing, choice, and duration of therapies. |
| doi_str_mv | 10.1007/s12029-022-00888-y |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2758112586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2758112586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-50851a4108a6d15075a2b2ade39b687e48e0dc29dae0a5ce44e0d40c5a48faba3</originalsourceid><addsrcrecordid>eNp9kMtu2zAQRYmiQZy4-YEuCi6zUUpSJEV1FyiPGsijKJw1MSLHrlw9ElJq4Hx9mdrJsivOgOdeYA4hnzk744wVXyMXTJQZEyJjzBiTbT-QI15Knmmd64_vszAzchzjhjEtFeeHZJZrpUWZmyPyu2qCm1oYm35Nl1M3BHpxd_6NLodnCD7S2yEgXfS--dP4CdrmBT1dBoSxw36kq4T_SNk0R_rcjL_oT4zoRqhbpNXQpnBaWlpB7zB8IgcraCOe7N85ebi6XFbfs5v760V1fpO5XBZjpphRHCRnBrTnihUKRC3AY17W2hQoDTLvROkBGSiHUqZdMqdAmhXUkM_J6a73MQxPE8bRdk102LbQ4zBFKwplOBfK6ISKHerCEGPAlX0MTQdhazmzr5LtTrJNku0_yXabQl_2_VPdoX-PvFlNQL4DYvrq1xjsZphCn27-X-1f63OJiw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2758112586</pqid></control><display><type>article</type><title>Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer</title><source>Springer Nature</source><creator>Adams, Alexandra M. ; Vreeland, Timothy J. ; Newhook, Timothy E.</creator><creatorcontrib>Adams, Alexandra M. ; Vreeland, Timothy J. ; Newhook, Timothy E.</creatorcontrib><description>Purpose
Despite curative-intent treatment, recurrence is common for patients with colorectal cancer (CRC). Currently, prediction of disease recurrence and prognostication following surgery is based upon vague clinical factors and more precise and dynamic biomarkers for risk stratification and treatment decisions are urgently needed. Circulating tumor DNA (ctDNA) is a promising biomarker for patients undergoing treatment for resectable CRC.
Methods
In this review, we provide an overview of the data supporting current uses of ctDNA for CRC, including localized CRC and resectable colorectal liver metastases (CLM), as well as descriptions of important ongoing clinical trials using ctDNA in the care of patients with CRC.
Results
The detection of ctDNA following curative-intent therapy is associated with disease recurrence, and multiple trials are investigating its role in determining need and duration for adjuvant therapy for localized CRC. In addition, ctDNA reliably predicts prognosis for patients with CLM, with trials underway studying ctDNA-guided treatment sequencing and intensity.
Conclusion
The detection of ctDNA is a sensitive and dynamic biomarker for disease recurrence in CRC. Many investigations are underway into ctDNA’s potential role in surveillance and treatment algorithms, and it has the potential to become a critical biomarker to determine individualized strategies for treatment sequencing, choice, and duration of therapies.</description><identifier>ISSN: 1941-6628</identifier><identifier>EISSN: 1941-6636</identifier><identifier>DOI: 10.1007/s12029-022-00888-y</identifier><identifier>PMID: 36562938</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers, Tumor - genetics ; Cancer Research ; Circulating Tumor DNA - genetics ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - surgery ; Gastroenterology ; Humans ; Internal Medicine ; Liver Neoplasms - diagnosis ; Liver Neoplasms - genetics ; Liver Neoplasms - surgery ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - genetics ; Oncology ; Prognosis ; Radiotherapy ; Review Article</subject><ispartof>Journal of gastrointestinal cancer, 2023-12, Vol.54 (4), p.1071-1081</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-50851a4108a6d15075a2b2ade39b687e48e0dc29dae0a5ce44e0d40c5a48faba3</citedby><cites>FETCH-LOGICAL-c347t-50851a4108a6d15075a2b2ade39b687e48e0dc29dae0a5ce44e0d40c5a48faba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36562938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adams, Alexandra M.</creatorcontrib><creatorcontrib>Vreeland, Timothy J.</creatorcontrib><creatorcontrib>Newhook, Timothy E.</creatorcontrib><title>Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer</title><title>Journal of gastrointestinal cancer</title><addtitle>J Gastrointest Canc</addtitle><addtitle>J Gastrointest Cancer</addtitle><description>Purpose
Despite curative-intent treatment, recurrence is common for patients with colorectal cancer (CRC). Currently, prediction of disease recurrence and prognostication following surgery is based upon vague clinical factors and more precise and dynamic biomarkers for risk stratification and treatment decisions are urgently needed. Circulating tumor DNA (ctDNA) is a promising biomarker for patients undergoing treatment for resectable CRC.
Methods
In this review, we provide an overview of the data supporting current uses of ctDNA for CRC, including localized CRC and resectable colorectal liver metastases (CLM), as well as descriptions of important ongoing clinical trials using ctDNA in the care of patients with CRC.
Results
The detection of ctDNA following curative-intent therapy is associated with disease recurrence, and multiple trials are investigating its role in determining need and duration for adjuvant therapy for localized CRC. In addition, ctDNA reliably predicts prognosis for patients with CLM, with trials underway studying ctDNA-guided treatment sequencing and intensity.
Conclusion
The detection of ctDNA is a sensitive and dynamic biomarker for disease recurrence in CRC. Many investigations are underway into ctDNA’s potential role in surveillance and treatment algorithms, and it has the potential to become a critical biomarker to determine individualized strategies for treatment sequencing, choice, and duration of therapies.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer Research</subject><subject>Circulating Tumor DNA - genetics</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - surgery</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Radiotherapy</subject><subject>Review Article</subject><issn>1941-6628</issn><issn>1941-6636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kMtu2zAQRYmiQZy4-YEuCi6zUUpSJEV1FyiPGsijKJw1MSLHrlw9ElJq4Hx9mdrJsivOgOdeYA4hnzk744wVXyMXTJQZEyJjzBiTbT-QI15Knmmd64_vszAzchzjhjEtFeeHZJZrpUWZmyPyu2qCm1oYm35Nl1M3BHpxd_6NLodnCD7S2yEgXfS--dP4CdrmBT1dBoSxw36kq4T_SNk0R_rcjL_oT4zoRqhbpNXQpnBaWlpB7zB8IgcraCOe7N85ebi6XFbfs5v760V1fpO5XBZjpphRHCRnBrTnihUKRC3AY17W2hQoDTLvROkBGSiHUqZdMqdAmhXUkM_J6a73MQxPE8bRdk102LbQ4zBFKwplOBfK6ISKHerCEGPAlX0MTQdhazmzr5LtTrJNku0_yXabQl_2_VPdoX-PvFlNQL4DYvrq1xjsZphCn27-X-1f63OJiw</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Adams, Alexandra M.</creator><creator>Vreeland, Timothy J.</creator><creator>Newhook, Timothy E.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231201</creationdate><title>Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer</title><author>Adams, Alexandra M. ; Vreeland, Timothy J. ; Newhook, Timothy E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-50851a4108a6d15075a2b2ade39b687e48e0dc29dae0a5ce44e0d40c5a48faba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer Research</topic><topic>Circulating Tumor DNA - genetics</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - surgery</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Radiotherapy</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adams, Alexandra M.</creatorcontrib><creatorcontrib>Vreeland, Timothy J.</creatorcontrib><creatorcontrib>Newhook, Timothy E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastrointestinal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adams, Alexandra M.</au><au>Vreeland, Timothy J.</au><au>Newhook, Timothy E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer</atitle><jtitle>Journal of gastrointestinal cancer</jtitle><stitle>J Gastrointest Canc</stitle><addtitle>J Gastrointest Cancer</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>54</volume><issue>4</issue><spage>1071</spage><epage>1081</epage><pages>1071-1081</pages><issn>1941-6628</issn><eissn>1941-6636</eissn><abstract>Purpose
Despite curative-intent treatment, recurrence is common for patients with colorectal cancer (CRC). Currently, prediction of disease recurrence and prognostication following surgery is based upon vague clinical factors and more precise and dynamic biomarkers for risk stratification and treatment decisions are urgently needed. Circulating tumor DNA (ctDNA) is a promising biomarker for patients undergoing treatment for resectable CRC.
Methods
In this review, we provide an overview of the data supporting current uses of ctDNA for CRC, including localized CRC and resectable colorectal liver metastases (CLM), as well as descriptions of important ongoing clinical trials using ctDNA in the care of patients with CRC.
Results
The detection of ctDNA following curative-intent therapy is associated with disease recurrence, and multiple trials are investigating its role in determining need and duration for adjuvant therapy for localized CRC. In addition, ctDNA reliably predicts prognosis for patients with CLM, with trials underway studying ctDNA-guided treatment sequencing and intensity.
Conclusion
The detection of ctDNA is a sensitive and dynamic biomarker for disease recurrence in CRC. Many investigations are underway into ctDNA’s potential role in surveillance and treatment algorithms, and it has the potential to become a critical biomarker to determine individualized strategies for treatment sequencing, choice, and duration of therapies.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36562938</pmid><doi>10.1007/s12029-022-00888-y</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-6628 |
| ispartof | Journal of gastrointestinal cancer, 2023-12, Vol.54 (4), p.1071-1081 |
| issn | 1941-6628 1941-6636 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2758112586 |
| source | Springer Nature |
| subjects | Biomarkers, Tumor - genetics Cancer Research Circulating Tumor DNA - genetics Colorectal Neoplasms - genetics Colorectal Neoplasms - surgery Gastroenterology Humans Internal Medicine Liver Neoplasms - diagnosis Liver Neoplasms - genetics Liver Neoplasms - surgery Medicine Medicine & Public Health Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - genetics Oncology Prognosis Radiotherapy Review Article |
| title | Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A04%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20Tumor%20DNA:%20Towards%20More%20Individualized%20Treatment%20for%20Patients%20with%20Resectable%20Colorectal%20Cancer&rft.jtitle=Journal%20of%20gastrointestinal%20cancer&rft.au=Adams,%20Alexandra%20M.&rft.date=2023-12-01&rft.volume=54&rft.issue=4&rft.spage=1071&rft.epage=1081&rft.pages=1071-1081&rft.issn=1941-6628&rft.eissn=1941-6636&rft_id=info:doi/10.1007/s12029-022-00888-y&rft_dat=%3Cproquest_cross%3E2758112586%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-50851a4108a6d15075a2b2ade39b687e48e0dc29dae0a5ce44e0d40c5a48faba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2758112586&rft_id=info:pmid/36562938&rfr_iscdi=true |